After the U.S. stock market opened on Tuesday, Pfizer,　　which has been deeply affected by the uncertainty of U.S. pharmaceutical policies this year,The company's stock price rose by over 4% at one point. Multiple sources indicate that Pfizer CEO Albert Bourla will visit the White House later on Tuesday to announce drug pricing policies and a $70 billion domestic investment plan with Trump.

( Pfizer daily chart, Source: TradingView)

In addition to Pfizer, many large pharmaceutical companies also rose .Bristol-Myers Squibb rose nearly 3%.Up 2%, AmgenUp 1%.
If the news is true, Pfizer has resolved at least two policy uncertainties : US President Trump once wrote to Pfizer and 16 other pharmaceutical companies asking for price cuts, and demanded that prices in the United States should not be more expensive than those in developed countries such as Europe (the "most favored nation" policy); Trump also announced tariffs on branded drugs last week, and the prerequisite for exemption is that "pharmaceutical companies must build factories in the United States."
It is not clear at this time what the specific price reductions will be for Pfizer's drugs, nor what range of drugs will be affected.
Trump set a September 29 deadline for drugmakers to lower prices and warned he would "use every available tool" to punish those that failed to act. The pharmaceutical industry strongly opposed this move and urged the Trump administration to turn its attention to drug middlemen.
Pfizer is reportedly voluntarily reducing its discounted prices for U.S. Medicare (Medicaid) and securing a three-year suspension of drug tariffs by building a factory in the U.S. To this end, Pfizer will announce a $70 billion R&D investment and domestic production expansion plan on Tuesday.
In response to the market news, Pfizer spokesperson Amy Ross said the agreement provides the company with the certainty and stability it needs to continue developing breakthrough new drugs.
The White House is also preparing to launch a direct-to-consumer drug sales website called "TrumpRx ." The website will offer cash purchases at government-rebated prices, and Pfizer will directly supply the platform. It's unclear whether this website will be practical for Americans with health insurance.
It's worth noting that Trump has long been fussy about the higher drug prices in the United States compared to Europe. Before the end of his first term, he enacted a similar "most-favored-nation" policy, but the provision was halted by a federal court due to procedural issues and subsequently rescinded by Biden in 2021.
Some industry experts pointed out that in order to cope with the "most-favored-nation" policy, pharmaceutical companies may not only lower prices themselves, but also meet the requirements by raising drug prices in other countries .
For example, Eli LillyThe company announced in August that it would raise the price of its GLP-1 drug Mufenad in the UK. Earlier this month, Bristol-Myers Squibb also said its schizophrenia drug Cobenfy would have the same list price in the UK as in the United States.

https://finance.eastmoney.com/a/202509303527750612.html